KALA

KALA is not a pharmaceutical company anymore in any operating sense — it is a distressed shell. Its lead candidate KPI-012 missed both primary endpoints in the CHASE Phase 2b trial in September 2025 and was discontinued along with the entire MSC-S platform, leaving the company with $0.00 of revenue for the third straight year (FY2023–FY2025). Management has pivoted to 'evaluating the development' of an on-premises AI infrastructure platform (Researgency) licensed from a third party — a revenue-less, buzzword-driven reverse-pivot layered on a biotech that just failed clinically. There is no product, no revenue, and no evidence the AI venture is anything more than optionality on a licensed asset.

The balance sheet is a wreck dressed up by prior write-downs. Cash fell 85% to $7.56M while operating cash burn ran -$32.0M in FY2025 — roughly a quarter of runway. Total assets collapsed 83% to $9.49M against a $694.9M accumulated deficit. The company triggered a $29.1M acceleration/default with Oxford Finance in September 2025, executed workforce terminations, and its own predecessor auditor flagged substantial-doubt going-concern language; management claims that doubt was 'alleviated,' but explicitly warns there is 'no assurance' its plans succeed and cites possible insolvency proceedings. Survival has depended on tiny, punishing raises — $1.2M in November 2025 and $4.2M in January 2026 — which is why shares outstanding exploded to 929M, up 14,305% year-over-year. ROE of -385.6% is meaningless given the tiny equity base; the signal is the dilution itself.